We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Futura Medical
FY21 is set to be a year of executionHUTCHMED
Baring Private Equity Asia invests $100mNexstim
Rights issue 178% oversubscribedHUTCHMED
Breaking new ground in China and globallyFutura Medical
EU Notified Body recommends MED3000 approvalNexstim
Subscription rights issue of €6.6m at €0.03 per shareHutchison China MediTech
Transitioning to a global oncology playerFutura Medical
Commercialisation deal for China and SE AsiaNexstim
A positive start to the 2020-24 strategyNexstim
Promising results for severe depression pilot study